Anzeige
Mehr »
Freitag, 19.09.2025 - Börsentäglich über 12.000 News
Die Ethereum-Vorreiter: Wie Republic Technologies die Infrastruktur der Zukunft aufbaut
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A0LA5K | ISIN: SE0000872095 | Ticker-Symbol: B6E
Tradegate
18.09.25 | 19:24
25,140 Euro
+0,56 % +0,140
1-Jahres-Chart
SWEDISH ORPHAN BIOVITRUM AB Chart 1 Jahr
5-Tage-Chart
SWEDISH ORPHAN BIOVITRUM AB 5-Tage-Chart
RealtimeGeldBriefZeit
24,88025,10008:25
24,90025,12008:25

Aktuelle News zur SWEDISH ORPHAN BIOVITRUM Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
08:24Swedish Orphan Biovitrum AB: Tryngolza (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)11STOCKHOLM, Sept. 19, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical company dedicated to delivering innovative treatments for patients with rare diseases, and Ionis Pharmaceuticals...
► Artikel lesen
08:09SWEDISH ORPHAN BIOVITRUM AB: Tryngolza (olezarsen) approved in the European Union for familial chylomicronemia syndrome (FCS)1
10.09.Swedish Orphan Biovitrum AB: Invitation: Sobi's NASP and Uncontrolled Gout call and webcast209NASP (previously known as SEL-212) - clinical program overview and uncontrolled gout disease landscape. STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Investors, analysts, and members of...
► Artikel lesen
10.09.Swedish Orphan Biovitrum AB: FDA Accepts Biologics License Application for Sobi's NASP for Patients with Uncontrolled Gout327Submission includes results of the pivotal DISSOLVE I and II studiesNASP PDUFA date set for 27 June 2026STOCKHOLM, Sept. 10, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), a global biopharmaceutical...
► Artikel lesen
29.08.Swedish Orphan Biovitrum AB: New number of shares and votes in Sobi260STOCKHOLM, Aug. 29, 2025 /PRNewswire/ -- As per 29 August 2025, the total number of shares in Swedish Orphan Biovitrum AB (publ) (Sobi®) amounts to 357,412,837 shares, of which 356,000,049...
► Artikel lesen
21.08.Swedish Orphan Biovitrum AB: Sobi has completed issues of class C shares209STOCKHOLM, Aug. 21, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025 resolved on directed issues of redeemable and convertible class...
► Artikel lesen
SWEDISH ORPHAN BIOVITRUM Aktie jetzt für 0€ handeln
25.07.Ionis Pharma, Sobi Get Positive CHMP Opinion For TRYNGOLZA In Familial Chylomicronemia Syndrome17
25.07.Sobi North America Announces Approval Of Doptelet For Pediatric ITP451STOCKHOLM (dpa-AFX) - Sobi North America, the North American affiliate of Swedish Orphan Biovitrum AB, announced the FDA approved Doptelet or avatrombopag for the treatment of thrombocytopenia...
► Artikel lesen
25.07.Swedish Orphan Biovitrum AB: TRYNGOLZA (olezarsen) recommended for EU approval by CHMP for familial chylomicronemia syndrome (FCS)433Recommendation based on Phase 3 Balance results, which showed a significant reduction of triglycerides and substantial reduction of acute pancreatitis events with TRYNGOLZAEuropean Commission...
► Artikel lesen
25.07.Sobi, Inc.: Sobi Announces U.S. Food and Drug Administration Approves Doptelet (avatrombopag) for the Treatment of Thrombocytopenia in Pediatric Patients One Year and Older with Persistent or Chronic Immune Thrombocytopenia ...187 Doptelet Sprinkle (avatrombopag) was approved as an effective formulation for children one year to less than six years. The primary endpoint was met in 27.8% of patients, confirming the efficacy in...
► Artikel lesen
16.07.Swedish Orphan Biovitrum AB Non-GAAP EPS of SEK 2.36, revenue of SEK 6.17B; reaffirms FY25 outlook6
16.07.Swedish Orphan Biovitrum AB: Sobi publishes Q2 2025 report: Continued strong portfolio and pipeline momentum389STOCKHOLM, July 16, 2025 /PRNewswire/ -- Swedish Orphan Biovitrum AB (publ) (Sobi®) today announced its report for the second quarter 2025 Second Quarter 2025 Total revenue increased...
► Artikel lesen
15.07.Swedish Orphan Biovitrum AB: The Board of Directors of Sobi exercises authorisation for repurchase of shares for the purpose of securing the company's commitments under incentive programmes462STOCKHOLM, July 15, 2025 /PRNewswire/ -- The Annual General Meeting of Swedish Orphan Biovitrum AB (publ) (Sobi®) on 8 May 2025, resolved - for the purpose of ensuring that the company can...
► Artikel lesen
02.07.Apellis Stock Rises on $300M Royalty Deal With Sobi for Aspaveli7
02.07.Swedish Orphan Biovitrum AB: Invitation: Sobi's Q2 report283Sobi plans to publish its report for the second quarter of 2025 on 16 July 2025 at 08:00 CEST. STOCKHOLM, July 2, 2025 /PRNewswire/ -- Investors, analysts, and the media are invited...
► Artikel lesen
02.07.Regulatory tracker: Sobi's Gamifant gains new FDA approval in Still's disease3
01.07.Sobi agrees to pay up to $300M to reduce royalty payments to Apellis on Empaveli4
01.07.Apellis stock rises after $300 million royalty deal with Sobi2
01.07.Apellis signs royalty purchase deal with Sobi for Aspaveli4
01.07.Swedish Orphan Biovitrum AB: Sobi to amend existing agreement with Apellis for ex-U.S. royalties of Aspaveli (systemic pegcetacoplan)506STOCKHOLM, July 1, 2025 /PRNewswire/ -- Sobi® (STO: SOBI), today announced a capped royalty purchase agreement with Apellis Pharmaceuticals, Inc. under which Sobi will reduce its ex-US royalty...
► Artikel lesen
Weiter >>
69 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1